Compare CYTK & ALLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | ALLY |
|---|---|---|
| Founded | 1997 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.5B |
| IPO Year | 2004 | 2011 |
| Metric | CYTK | ALLY |
|---|---|---|
| Price | $75.87 | $43.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 13 |
| Target Price | ★ $89.26 | $54.42 |
| AVG Volume (30 Days) | 1.8M | ★ 2.9M |
| Earning Date | 05-05-2026 | 04-17-2026 |
| Dividend Yield | N/A | ★ 2.74% |
| EPS Growth | N/A | ★ 31.67 |
| EPS | N/A | ★ 2.11 |
| Revenue | $13,368,000.00 | ★ $7,914,000,000.00 |
| Revenue This Year | $7.37 | $24.30 |
| Revenue Next Year | $310.19 | $4.31 |
| P/E Ratio | ★ N/A | $21.28 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.22 | $35.92 |
| 52 Week High | $88.31 | $47.29 |
| Indicator | CYTK | ALLY |
|---|---|---|
| Relative Strength Index (RSI) | 41.75 | 47.61 |
| Support Level | $73.95 | $43.44 |
| Resistance Level | $80.65 | $46.94 |
| Average True Range (ATR) | 2.94 | 0.89 |
| MACD | -0.58 | 0.07 |
| Stochastic Oscillator | 26.45 | 51.37 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.